T1	Chemical 32 40	low-dose
T2	Chemical 97 119	antiangiogenic effects
T5	Disease 208 235	haematological malignancies
T6	Chemical 237 255	Thalidomide blocks
T8	Chemical 272 289	angiogenic agents
T9	Chemical 300 304	bFGF
T10	Chemical 306 310	VEGF
T11	Chemical 315 319	IL-6
T12	Chemical 360 378	thalidomide 100 mg
T13	Chemical 572 597	prostate-specific antigen
T17	Chemical 634 638	bFGF
T18	Chemical 643 647	VEGF
T21	Chemical 874 878	bFGF
T22	Chemical 883 887	VEGF
T23	Disease 909 928	progressive disease
T25	Chemical 1002 1006	bFGF
T26	Chemical 1011 1015	VEGF
T28	Chemical 1091 1105	growth factors
T29	Disease 1107 1122	Adverse effects
T31	Disease 1146 1164	morning drowsiness
T35	Disease 1254 1283	peripheral sensory neuropathy
T37	Disease 1412 1433	peripheral neuropathy
T40	Disease 1673 1694	peripheral neuropathy
